Newsroom


The latest featured press and company announcements from Genomenon.

For general press inquiries, please contact Colleen McMillen, VP of Marketing: cmcmillen@genomenon.com

2,000
Clinical Labs rely on Mastermind
50%
of the clinical exome has been curated by Genomenon
100+
Grad-level Scientists power Genomenon’s genomic intelligence development
145+
Countries around the world have labs powered by Mastermind

News

Read the latest coverage featuring Genomenon.

Sep 23, 2024
High-Growth Companies Honored Fasttrack Awards 2024
May 16, 2024
Genomenon Combines AI Scientist Curation Gene-Disease Insights
May 9, 2024
Genomenon Acquired Variant Database, Team Jackson Laboratory
May 2, 2024
Genomenon Partners Pharming Improve Diagnosis Rare Immunodeficiency Syndrome
Mar 29, 2024
An Established Relationship: How semi-automated biomedical evidence curation could open up genetic diagnostics
Mar 15, 2024
Genomenon Combines AI with Scientist Curation to Offer Gene-Disease Insights
Jan 3, 2024
Trendspotting: What’s Coming for Diagnostics in 2024
Jan 3, 2024
Trendspotting: What’s Coming Biotech 2024
Jan 3, 2024
Trendspotting: What’s Coming Clinical Trials Research 2024
Jan 3, 2024
Trendspotting: What’s Coming Diagnostics 2024
Dec 11, 2023
Current Advances Future Directions Rare Disease Diagnosis
Dec 6, 2023
Genomenon Curate-Pro, Interpret
Dec 5, 2023
Curation On-Demand Service for Genetic Testing Labs Debuts
Nov 2, 2023
Genomenon Delivers Fully Curated Clinical Exome Mastermind 3 Release ASHG
Aug 10, 2023
When Your Data Too Much Process, Turn AI/ML
Jul 20, 2023
AI Company Aims Curate Entire Human
Jul 11, 2023
Genomenon Acquires Boston Genetics Rapid Human Genome Curation
Jun 30, 2023
Genomenon Accelerates Quest Curate Entire Human Genome Boston Genetics Acquisition
Jun 29, 2023
Genomenon Acquires Boston Genetics Accelerate Curation of Human Genome
Jun 28, 2023
Genomenon Ann Arbor Acquires Boston Genetics Speed Curation Human Genome
Jun 27, 2023
Genomenon Acquires Boston Genetics Accelerate Curation Human Genome
Jun 27, 2023
Genomics AI Firm Genomenon Acquires Boston Genetics
Jun 27, 2023
Genomics AI Genomenon Acquires Boston Genetics
Feb 7, 2023
Genomenon, Flagship Biosciences Partner Biomarker Discovery, Companion Dx Development
Feb 6, 2023
Flagship Biosciences Genomenon Partner Advance Precision Medicine Development
Jan 9, 2023
Genomenon Named Top Ann Arbor Tech Company 2023
Dec 5, 2022
Partnership Hopes Advance Precision Drug Development
Dec 2, 2022
Rare Disease Revolution
Nov 30, 2022
Genomenon Inks AI/Genomics Deal Three Rare Neuro-Disease Orgs
Nov 30, 2022
Genomenon, Nonprofits Team Up Genomic Data Rare Diseases
Nov 29, 2022
Genomenon Collaborates Rare Disease Foundations Drug Development
Nov 29, 2022
Genomenon Partners Neurodevelopmental Disease Groups Drug Development
Nov 1, 2022
Genomenon publishes ENPP1 deficiency database
Oct 31, 2022
Novel Solution Increases Diagnostic Yield, Accelerates Rare Disease Diagnoses
Sep 27, 2022
Increasing Biologics Manufacturing Efficiency Lowering Costs QbD
Sep 7, 2022
Genomenon Mastermind ClinVar
Sep 6, 2022
Genomenon Integrates NIH Variant Data Mastermind
Aug 25, 2022
BeginNGS Program Pediatric Rare Disease Dx, Treatment Rapid NGS, Data Curation
Aug 24, 2022
Novel newborn screening whole genome sequencing acute management guidance screen diagnosis genetic diseases
Aug 2, 2022
Genomenon Curate Genes Rady Children's BeginNGS Newborn Screening Panel
Jul 26, 2022
Study potential genome treatment guide physicians genetic diseases
Jul 26, 2022
Automated Genome Treatment System Help Manage Genetic Disease
Jul 25, 2022
New consortium leverages infant screening accelerate treatment
Jun 14, 2022
Rady Children’s Evaluate Scalability Rapid WGS 400 Known Genetic Diseases
Jun 14, 2022
Rady Children’s Institute launches newborn genetic disease screening
Jun 8, 2022
New Partnership Aims Improve Genomic Variant Interpretation
Jun 7, 2022
Agilent Integrate Genomenon Search Engine, Accelerate Workflows Nvidia
Jun 6, 2022
Curation Entire Human Genome Requires Human Artificial Intelligence
Mar 12, 2022
Genomenon Wins Best Show Bio-IT World Conference & Expo 2022
Mar 10, 2022
Ann Arbor Software Firm Genomenon $20 Million Funding Round
Feb 28, 2022
Ultimate Vision Rare Disease
Feb 24, 2022
Genomenon Forges Rare-Disease Partnership Advocacy Group
Feb 23, 2022
Genomenon Partners Don’t Forget Morgan Provide Hope Rare Disease
Feb 22, 2022
Genomenon Partners Rare-Disease Charity Variant Identification
Feb 16, 2022
Human Genome Requires Interpretation. AI Can Make Happen
Feb 15, 2022
Genomenon Wins NIH SBIR Grant Accelerate Variant Interpretation
Feb 15, 2022
Genomenon Scores SBIR Grant Curate Genetic Drivers Disease
Jan 31, 2022
Mike Klein Genomenon’s Technology Impact Overall Wellness
Jan 5, 2022
Genomenon OmniTier Partner Mastermind’s Evidence Sources CompStor Insight
Jan 5, 2022
Genomenon, OmniTier Integrate Genome Analysis Technologies

Announcements

Events

Meet the Genomenon team at one of the following industry events:

October 9, 2024

ICONS - International Conference on Newborn Screening

Boston, MA
ICoNS is an alliance of genomic scientists and stakeholders who share a vision of responsibly implementing newborn sequencing to predict treatable disease in babies and intervene before symptoms begin.
November 5, 2024

ASHG 2024 Annual Meeting

Denver, CO
The ASHG Conference is the world's largest human genetics and genomics meeting and exposition, providing a forum for the presentation and discussion of cutting-edge science in all areas of human genetics. The Genomenon team will be on the show flloor at booth # 757. We’ll be posting more details soon on our scientific talks.
November 19, 2024

Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo

Vancouver, BC, Canada
The AMP Annual Meeting brings together professionals in molecular diagnostics and genomics to share knowledge, advances, and best practices in the field, with a focus on improving patient care and outcomes. The Genomenon and CKB team will be on the show floor at booth # 1233. We’ll be posting more details soon on our scientific talks.